E Psychedelic Drug Stocks Index Continues To Appreciate In Value

* indicates that the stock is also a constituent in the new - and tradable - Horizons Psychedelic Stock Index ETF (PSYK) which began trading on the Canadian NEO Exchange on January 26th at C$9.43 and closed at C$11.25 this week up 21.8% as compared to the munKNEE Pure-Play Psychedelic Drug Stocks index which was up 24.0% from the beginning of the month. The Horizon Index, however, is not a pure-play ETF in that it also includes Johnson & Johnson, AbbVie Inc. and Greenbrook TMS Inc. who are not directing 100% of their efforts into the research and development of psychedelic components for medical applications. The  munKNEE Pure-Play Psychedelic Drug Stocks Index, on the other hand, is a pure-play and, as such, provides a true picture of the health and trend of this new stock sector. 

Please Note: Company names above have been hyperlinked to their corporate web sites and every company trading symbol has been hyperlinked to stock charts, in-depth financial data, and links to other articles on the company to enable the reader to do their due diligence before making a decision to invest in any stock mentioned. Also, keep in mind that some stocks in this sector trade for less than $1/share (i.e. are penny stocks) and may be susceptible to manipulation by unscrupulous speculators. All prices are in USD unless otherwise noted. Go here to convert to another currency.

Investing in small-cap stocks is speculative but, given the recent returns on psychedelic drug stocks, few investment opportunities of any kind, in any market, can equal the potential returns from this sector.

1 2
View single page >> |

Visit  munKNEE.com and register to receive our free Market Intelligence Report newsletter (sample  more

How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.